Models of patient engagement for Alzheimer’s disease


Start Date
End Date
IMI2 - Call 5
Grant agreement number

IMI Funding
2 043 000
EFPIA in kind
1 967 251
Total Cost4 010 251


Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and determine which models work best in different situations. As well as adding to our understanding of the earliest stages of dementia, the project will facilitate recruitment for clinical trials and, most importantly, ensure that patients are able to access support from early on in their disease.

Participants Show participants on map

EFPIA companies
  • AstraZeneca AB, Södertälje, Sweden
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • European Institute Of Women'S Health Limited, Dublin, Ireland
  • Fundacio ACE. Institut Catala de Neurosciences Aplicades , Barcelona , Spain
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Karolinska Institutet, Stockholm, Sweden
  • Stichting VU, Amsterdam, Netherlands
  • University Hospital of Cologne, Cologne, Germany
  • Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • ASDM Consulting, Bruxelles, Belgium
  • GMV Soluciones Globales Internet S.A.U., Tres Cantos, Spain
  • Kite Innovation (Europe) Limited, Huddersfield, United Kingdom
Patient organisations
  • Alzheimer Europe, Luxembourg, Luxembourg
  • Slovensko združenje za pomoč pri demenci - Spominčica, Alzheimer Slovenija, Ljubljana, Slovenia


Project coordinator
Merce Boada
Fundacio ACE. Institut Catala de Neurosciences Aplicades
Project leader
Laura Campo
Eli & Lilly